# A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07776509` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07776509](<https://clinicaltrials.gov/study/NCT07776509>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07776509

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT07776509. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2028-08-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT07776509, source copy `cardio:ctgov-nct07776509-2026-11-09`, retrieved 2026-11-18)
- Started: 2026-08-24 (actual) (ClinicalTrials.gov record NCT07776509, source copy `cardio:ctgov-nct07776509-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2028-08-09 (anticipated) (ClinicalTrials.gov record NCT07776509, source copy `cardio:ctgov-nct07776509-2026-11-09`, retrieved 2026-11-18)
- Completion: 2028-08-09 (anticipated) (ClinicalTrials.gov record NCT07776509, source copy `cardio:ctgov-nct07776509-2026-11-09`, retrieved 2026-11-18)
- Countries: United States; Argentina; Brazil; Canada; China; Denmark; Israel; Japan; Sweden; Türkiye; United Kingdom (ClinicalTrials.gov record NCT07776509, source copy `cardio:ctgov-nct07776509-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07776509-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Acronym: SELENE 3
- Condition: Obesity or Overweight
- Condition: Weight-Related Comorbidity
- Condition: With/Without Diabetes Mellitus, Type 2
- Intervention (Drug): Lenbelintide
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 0e4ea31d1532f8d8476b8b827e97b92159e759a238547a50cabc9aa6d1ddc399
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
